Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy

A post hoc analysis

Syed M. Mohiuddin, Kamlesh M. Thakker, Carolyn M. Setze, Maureen T. Kelly

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: To evaluate the achievement of individual and combined lipid and lipoprotein/biomarker targets as specified by treatment guidelines with the combination of fenofibric acid and statin therapy in patients with mixed dyslipidemia. Methods: Data for the post hoc analyses were derived from three 12-week controlled studies and a 52-week extension study. Patients were treated with fenofibric acid 135 mg; low-, moderate-, or high-dose statin (rosuvastatin 10, 20, or 40 mg; atorvastatin 20, 40, or 80 mg; or simvastatin 20, 40, or 80 mg); or fenofibric acid + low- or moderate-dose statin in the controlled studies; and with fenofibric acid + moderate-dose statin in the extension study. Achievement of risk-stratified low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), and apolipoprotein B (ApoB) targets; and optimal levels of ApoB 40/50 mg/dL in men/women, triglycerides (TG)

Original languageEnglish
Pages (from-to)1067-1078
Number of pages12
JournalCurrent Medical Research and Opinion
Volume27
Issue number5
DOIs
StatePublished - May 2011

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Dyslipidemias
Lipids
Apolipoproteins B
Simvastatin
Therapeutics
LDL Cholesterol
Lipoproteins
Triglycerides
Biomarkers
Guidelines
fenofibric acid

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy : A post hoc analysis. / Mohiuddin, Syed M.; Thakker, Kamlesh M.; Setze, Carolyn M.; Kelly, Maureen T.

In: Current Medical Research and Opinion, Vol. 27, No. 5, 05.2011, p. 1067-1078.

Research output: Contribution to journalArticle

@article{a650ab8e828f47e1882694a22dbce6b0,
title = "Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy: A post hoc analysis",
abstract = "Objective: To evaluate the achievement of individual and combined lipid and lipoprotein/biomarker targets as specified by treatment guidelines with the combination of fenofibric acid and statin therapy in patients with mixed dyslipidemia. Methods: Data for the post hoc analyses were derived from three 12-week controlled studies and a 52-week extension study. Patients were treated with fenofibric acid 135 mg; low-, moderate-, or high-dose statin (rosuvastatin 10, 20, or 40 mg; atorvastatin 20, 40, or 80{\^a}€‰mg; or simvastatin 20, 40, or 80 mg); or fenofibric acid + low- or moderate-dose statin in the controlled studies; and with fenofibric acid + moderate-dose statin in the extension study. Achievement of risk-stratified low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), and apolipoprotein B (ApoB) targets; and optimal levels of ApoB 40/50 mg/dL in men/women, triglycerides (TG)",
author = "Mohiuddin, {Syed M.} and Thakker, {Kamlesh M.} and Setze, {Carolyn M.} and Kelly, {Maureen T.}",
year = "2011",
month = "5",
doi = "10.1185/03007995.2011.569018",
language = "English",
volume = "27",
pages = "1067--1078",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy

T2 - A post hoc analysis

AU - Mohiuddin, Syed M.

AU - Thakker, Kamlesh M.

AU - Setze, Carolyn M.

AU - Kelly, Maureen T.

PY - 2011/5

Y1 - 2011/5

N2 - Objective: To evaluate the achievement of individual and combined lipid and lipoprotein/biomarker targets as specified by treatment guidelines with the combination of fenofibric acid and statin therapy in patients with mixed dyslipidemia. Methods: Data for the post hoc analyses were derived from three 12-week controlled studies and a 52-week extension study. Patients were treated with fenofibric acid 135 mg; low-, moderate-, or high-dose statin (rosuvastatin 10, 20, or 40 mg; atorvastatin 20, 40, or 80 mg; or simvastatin 20, 40, or 80 mg); or fenofibric acid + low- or moderate-dose statin in the controlled studies; and with fenofibric acid + moderate-dose statin in the extension study. Achievement of risk-stratified low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), and apolipoprotein B (ApoB) targets; and optimal levels of ApoB 40/50 mg/dL in men/women, triglycerides (TG)

AB - Objective: To evaluate the achievement of individual and combined lipid and lipoprotein/biomarker targets as specified by treatment guidelines with the combination of fenofibric acid and statin therapy in patients with mixed dyslipidemia. Methods: Data for the post hoc analyses were derived from three 12-week controlled studies and a 52-week extension study. Patients were treated with fenofibric acid 135 mg; low-, moderate-, or high-dose statin (rosuvastatin 10, 20, or 40 mg; atorvastatin 20, 40, or 80 mg; or simvastatin 20, 40, or 80 mg); or fenofibric acid + low- or moderate-dose statin in the controlled studies; and with fenofibric acid + moderate-dose statin in the extension study. Achievement of risk-stratified low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), and apolipoprotein B (ApoB) targets; and optimal levels of ApoB 40/50 mg/dL in men/women, triglycerides (TG)

UR - http://www.scopus.com/inward/record.url?scp=79954506700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954506700&partnerID=8YFLogxK

U2 - 10.1185/03007995.2011.569018

DO - 10.1185/03007995.2011.569018

M3 - Article

VL - 27

SP - 1067

EP - 1078

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 5

ER -